Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02571777
Recruitment Status : Recruiting
First Posted : October 8, 2015
Last Update Posted : July 16, 2018
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The purpose of the trial is to evaluate the efficacy and safety of two different doses of QVM149 (QVM149 150/50/80 μg and QVM149 150/50/160 μg via Concept1) over two respective QMF149 doses (QMF149 150/160 μg and QMF149 150/320 μg via Concept1 in poorly controlled asthmatics as determined by pulmonary function testing and effects on asthma control.

Condition or disease Intervention/treatment Phase
Asthma Drug: QVM149 Drug: QMF149 Drug: salmeterol/fluticasone Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2980 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, 52-week, Double-blind, Parallelgroup, Active Controlled Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma
Actual Study Start Date : February 1, 2015
Estimated Primary Completion Date : June 3, 2019
Estimated Study Completion Date : June 3, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Experimental: QVM149 150/50/160 µg o.d.
QVM149 150/50/160 µg o.d. delivered via Concept1
Drug: QVM149
Experimental: QVM149 150/50/80 µg o.d.
QVM149 150/50/80 µg o.d. delivered via Concept1
Drug: QVM149
Active Comparator: QMF149 150/160 µg o.d.
QMF149 150/160 µg o.d. delivered via Concept1
Drug: QMF149
Active Comparator: QMF149 150/320 µg o.d.
QMF149 150/320 µg o.d. delivered via Concept1
Drug: QMF149
Active Comparator: Salmeterol/fluticasone
Salmeterol xinafoate /fluticasone propionate 50/500 µg b.i.d. delivered via Accuhaler®.
Drug: salmeterol/fluticasone



Primary Outcome Measures :
  1. Trough FEV1 [ Time Frame: 26 weeks ]
    to demonstrate superiority of either QVM149 150/50/80 µg o.d. to QMF149 150/160 µg o.d. or QVM149 150/50/160 µg o.d. to QMF149 150/320 µg o.d on through FEV1 over 26 weeks of treatment. Forced Expiratory cvolume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.


Secondary Outcome Measures :
  1. Trough FEV1 at week 52 [ Time Frame: 52 weeks ]
    Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.

  2. FVC at week 4 and week 12 [ Time Frame: 12 weeks ]
    FVC is the total amount of air exhaled during the FEV test.

  3. PEF over 26 and 52 weeks [ Time Frame: 52 weeks ]
    measured in the morning and evening. PEF is the peak expiratory flow, the maximum speed of expiration.

  4. ACQ-7 [ Time Frame: 26 weeks, 52 weeks ]
    ACQ is the Asthma Control Questionnaire (scoring 5 symptoms, FEV1 entered by the investigator and the rescue medication use entered by the patient) validated to evaluate different levels of asthma control

  5. % days with no symptoms (overall, at awakening and rising) [ Time Frame: 52 weeks ]
    Percentage of days with no symptoms, the percentage of days with no awakenings and the percentage of mornings with no symptoms on rising

  6. % days without rescue medication use over 26 and 52 weeks [ Time Frame: 52 weeks ]
    Percentage of days without rescue medication usage (salbutamol(albuterol) as recorded by e-diary over 26 and 52 weeks of treatment.

  7. % patients with MID ACQ>= 0,5 at week 26 and 52 [ Time Frame: 52 weeks ]
    Percentage of patients achieving the minimal important difference (MID) ACQ ≥ 0.5 at Week 26 and Week 52

  8. asthma exacerbation over 52 weeks [ Time Frame: 52 weeks ]

    To evaluate the efficacy in terms of asthma exacerbation-related parameters :

    • Time to first hospitalization for asthma exacerbation
    • Time to first asthma exacerbation by exacerbation category
    • Annual rate of asthma exacerbations excluding measurements in patients requiring chronic corticosteroid use after an exacerbation (beyond permitted steroid taper for exacerbation) by exacerbation category
    • Duration in days of asthma exacerbations by exacerbation category
    • Percentage of patients with at least one asthma exacerbation by exacerbation category
    • Time in days to permanent discontinuation of study medication due to asthma exacerbations
    • Percentage of patients who permanently discontinued study medication due to asthma exacerbations
    • Total amounts of systemic corticosteroids (in doses) used to treat asthma exacerbations.

  9. % rescue medication free days over 26 and 52 weeks [ Time Frame: 52 weeks ]
    % of rescue medication free days over 26 and 52 weeks of treatment

  10. AQLQ [ Time Frame: 52 weeks ]
    Quality of life as assessed by Asthma Quality of Life Questionnaire (AQLQ) over 52 weeks

  11. Trough FEV1 at 26 weeks comparison with salmeterol xinafoate /fluticasone propionate 50/500 µg via Accuhaler® [ Time Frame: 26 weeks ]
    In addition to the comparison QVM149 150/50/80 µg o.d. to QMF149 150/160 µg o.d. or QVM149 150/50/160 µg o.d. to QMF149 150/320 µg o.d for all above endpoints, QVM149 150/50/80 µg o.d. and QVM149 150/50/160 µg o.d. delivered via Concept1 will be compared with salmeterol xinafoate /fluticasone propionate 50/500 µg via Accuhaler® in all secondary enpoints above as well as Trough FEV1 measured after 26 weeks of treatment

  12. Asthma control as assessed by the Asthma Control Questionnaire (ACQ-7) comparison with salmeterol xinafoate /fluticasone propionate 50/500 µg via Accuhaler® [ Time Frame: 26 weeks ]
    In addition to the comparison QVM149 150/50/80 µg o.d. to QMF149 150/160 µg o.d. or QVM149 150/50/160 µg o.d. to QMF149 150/320 µg o.d for all above endpoints, QVM149 150/50/80 µg o.d. and QVM149 150/50/160 µg o.d. delivered via Concept1 will be compared with salmeterol xinafoate /fluticasone propionate 50/500 µg via Accuhaler® in all secondary enpoints and ACQ-7 at week 26

  13. Serious asthma outcome incidence and CCV events/atrial fibrilaltion [ Time Frame: 52 weeks ]
    Cumulative incidence of the composite endpoint of serious asthma outcomes (i.e. asthma-related hospitalization, asthma-related intubation, or asthma-related death) and CCV events/atrial fibrillation over 52 weeks of treatment

  14. Adverse events, vital signs, laboratory analysis and ECG [ Time Frame: 52 weeks ]
    Adverse events, vital signs, ECG and laboratory analysis (haematology, blood chemistry including glucose and potassium, urinalysis, plasma evening cortisol) and treatment discontinuation due to adverse event over 52 weeks of treatment.

  15. FEV1 at week 4 and week 12 [ Time Frame: week 12 ]
    Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with a diagnosis of asthma, (GINA 2015) for a period of at least 1 year prior to Visit 1 (Screening).
  • Patients who have used medium or high dose of ICS/LABA combinations for asthma for at least 3 months and at stable medium or high doses of ICS/LABA for at least 1 month prior to Visit 1.
  • Patients must be symptomatic at screening despite treatment with mid or high stable doses of ICS/LABA. Patients with ACQ-7 score ≥ 1.5 at Visit 101 and at Visit 102 (before randomization).
  • Patients with documented history of at least one asthma exacerbation which required medical care from a physician, ER visit (or local equivalent structure) or hospitalization in the 12 months prior to Visit 1, and required systemic corticosteroid treatment.
  • Pre-bronchodilator FEV1 of < 80 % of the predicted normal value for the patient according to ATS/ERS guidelines after withholding bronchodilators at both visits 101 and 102.
  • Withholding period of bronchodilators prior to spirometry: SABA for ≥ 6 hrs, Twice daily LABA (or FDC of ICS/LABA) for ≥ 12 hrs, Once daily LABA (or FDC of ICS/LABA) for ≥ 24 hrs, SAMA for ≥ 8 hrs, Short acting xanthines for 12 hrs, Long acting xanthines for 24 hrs, .
  • Washout period of each drug should be kept as close as possible as above and should not be longer. If longer washout period is needed due to scheduling issues, please contact Novartis Medical monitor.
  • A one-time repeat of percentage predicated FEV1 (Pre-bronchodilator) at Visit 101 and/or Visit 102 is allowed in an ad-hoc visit. Repeat of Visit 101 spirometry should be done in an ad-hoc visit to be scheduled on a date that would provide sufficient time to receive confirmation from the spirometry data central reviewer of the validity of the assessment before randomization. Run-in medication should be dispensed once spirometry assessment met inclusion criteria (ATS/ERS quality criteria, FEV1 % predicted normal value, and reversibility) as per equipment
  • A one-time rescreen is allowed in case the patient fails to meet the criteria at the repeat, provided the patient returned to the required treatment as per inclusion criteria 4
  • Patients who demonstrate an increase in FEV1 of 12% and 200 mL within 30 minutes after administration of 400 µg salbutamol/360 µg albuterol (or equivalent dose) at Visit 101.All patients must perform a reversibility test at Visit 101. If reversibility is not demonstrated at Visit 101 then one of the following criteria need to be met.
  • Reversibility should be repeated once.
  • Patients may be permitted to enter the study with historical evidence of reversibility that was performed according to ATS/ERS guidelines within 2 years prior to Visit 1.
  • Alternatively, patients may be permitted to enter the study with a historical positive bronchoprovocation test that was performed within 2 years prior to Visit 1. If reversibility is not demonstrated at Visit 101 (or after repeated assessment in an ad-hoc visit) and historical evidence of reversibility/bronchoprovocation is not available (or was not performed according to the ATS/ERS guidelines patients must be screen failed
  • Spacer devices are permitted during reversibility testing only. The Investigator or delegate may decide whether or not to use a spacer for the reversibility testing

Exclusion Criteria:

  • Patients who have had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 6 weeks of Visit 1 (Screening). If patients experience an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit between Visit 1 and Visit 102 they may be re-screened 6 weeks after recovery from the exacerbation.
  • Patients who have ever required intubation for a severe asthma attack/exacerbation.
  • Patients who have a clinical condition which is likely to be worsened by ICS administration (e.g. glaucoma, cataract and fragility fractures) who are according to investigator's medical judgment at risk participating in the study.
  • Patients treated with a LAMA for asthma within 3 months prior Visit 1 (Screening).
  • Patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia (BPH) or bladder-neck obstruction or severe renal impairment or urinary retention. BPH patients who are stable on treatment can be considered).
  • Patients who have had a respiratory tract infection or asthma worsening as determined by investigator within 4 weeks prior to Visit 1 (Screening) or between Visit 1 and Visit 102. Patients may be re-screened 4 weeks after recovery from their respiratory tract infection or asthma worsening.
  • Patients with evidence upon visual inspection (laboratory culture is not required) of clinically significant (in the opinion of investigator) oropharyngeal candidiasis at Visit 102 or earlier, with or without treatment. Patients may be re-screened once their candidiasis has been treated and has resolved.
  • Patients with any chronic conditions affecting the upper respiratory tract (e.g. chronic sinusitis) which in the opinion of the investigator may interfere with the study evaluation or optimal participation in the study.
  • Patients with a history of chronic lung diseases other than asthma, including (but not limited to) chronic obstructive pulmonary disease, sarcoidosis, interstitial lung disease, cystic fibrosis, clinically significant bronchiectasis and active tuberculosis.
  • Patients with Type I diabetes or uncontrolled Type II diabetes.
  • Patients who, either in the judgment of the investigator or the responsible Novartis personnel, have a clinically significant condition such as (but not limited to) unstable ischemic heart disease, New York Heart Association (NYHA) Class III/IV left ventricular failure arrhythmia, uncontrolled hypertension, cerebrovascular disease, psychiatric disease, neurodegenerative diseases, or other neurological disease, uncontrolled hypo- and hyperthyroidism and other autoimmune diseases, hypokalemia, hyperadrenergic state, or ophthalmologic disorder or patients with a medical condition that might compromise patient safety or compliance, interfere with evaluation, or preclude completion of the study.
  • Patients with paroxysmal (e.g., intermittent) atrial fibrillation are excluded. Patients with persistent atrial fibrillation as defined by continuous atrial fibrillation for at least 6 months and controlled with a rate control strategy (i.e., selective beta blockers, calcium channel blocker, pacemaker placement, digoxin or ablation therapy) for at least 6 months may be considered for inclusion. In such patients, atrial fibrillation must be present at the run-in visit (Visit 101) with a resting ventricular rate < 100/min. At Visit 101 the atrial fibrillation must be confirmed by central reading.
  • Patients with a history of myocardial infarction (this should be confirmed clinically by the investigator) within the previous 12 months.
  • Concomitant use of agents known to prolong the QT interval unless it can be permanently discontinued for the duration of study
  • Patients with a history of long QT syndrome or whose QTc measured at Visit 101 (Fridericia method) is prolonged (> 450 msec for males and > 460 msec for females) and confirmed by a central assessor (these patients should not be rescreened).
  • Patients with a history of hypersensitivity to lactose, any of the study drugs or to similar drugs within the class including untoward reactions to sympathomimetic amines or inhaled medication or any component thereof.
  • Patients who have not achieved an acceptable spirometry result at Visit 101 in accordance with ATS/ERS criteria for acceptability and repeatability. A one-time repeat spirometry is allowed in an ad-hoc visit scheduled as close as possible from the first attempt (but not on the same day) if the spirometry did not qualify due to ATS/ERS criteria at Visit 101 and/or Visit 102. If the patient fails the repeat assessment, the patient may be rescreened once, provided the patient returns to the required treatment as per inclusion criteria 4.
  • Patients unable to use the Concept1 dry powder inhaler, Accuhaler or a metered dose inhaler. Spacer devices are not permitted.
  • History of alcohol or other substance abuse.
  • Patients with a known history of non-compliance to medication or who were unable or unwilling to complete a patient diary or who are unable or unwilling to use Electronic Peak Flow with e-diary device.
  • Patients who do not maintain regular day/night, waking/sleeping cycles (e.g., night shift workers).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02571777


Contacts
Layout table for location contacts
Contact: Novartis Pharmaceuticals +41613241111
Contact: Novartis Pharmaceuticals +81337978748

Locations
Hide Hide 481 study locations
Layout table for location information
Argentina
Novartis Investigative Site Recruiting
Bahia Blanca, Buenos Aires, Argentina, 8000
Novartis Investigative Site Recruiting
Caba, Buenos Aires, Argentina, C1056ABJ
Novartis Investigative Site Recruiting
Caba, Buenos Aires, Argentina, C1414AIF
Novartis Investigative Site Recruiting
Florida, Buenos Aires, Argentina, B1602DQD
Novartis Investigative Site Recruiting
Lanus, Buenos Aires, Argentina, B8000XAV
Novartis Investigative Site Recruiting
Mar del Plata, Buenos Aires, Argentina, 7600
Novartis Investigative Site Recruiting
Mar del Plata, Buenos Aires, Argentina, B7600FZN
Novartis Investigative Site Recruiting
San Nicolas, Buenos Aires, Argentina, B2900JUB
Novartis Investigative Site Recruiting
Vicente Lopez, Buenos Aires, Argentina, B1602DOH
Novartis Investigative Site Recruiting
Villa Maria, Cordoba, Argentina, X5900JKA
Novartis Investigative Site Recruiting
Concepcion del Uruguay, Entre Rios, Argentina, 3260
Novartis Investigative Site Recruiting
Godoy Cruz, Mendoza, Argentina, M5500EOB
Novartis Investigative Site Recruiting
Santa Fe, Rosario, Argentina, S2000DBS
Novartis Investigative Site Recruiting
Rosario, Santa Fe, Argentina, 2000
Novartis Investigative Site Recruiting
Rosario, Santa Fe, Argentina, S2000CXH
Novartis Investigative Site Recruiting
Rosario, Santa Fe, Argentina, S2000DBS
Novartis Investigative Site Recruiting
Rosario, Santa Fe, Argentina, S2000DSV
Novartis Investigative Site Recruiting
Rosario, Santa Fe, Argentina, S2000JKR
Novartis Investigative Site Recruiting
Rosario, Santa Fe, Argentina, S2000QID
Novartis Investigative Site Recruiting
San Miguel de Tucuman, Tucuman, Argentina, 4000
Novartis Investigative Site Recruiting
Buenos Aires, Argentina, B1646EBJ
Novartis Investigative Site Recruiting
Buenos Aires, Argentina, B1842DID
Novartis Investigative Site Recruiting
Buenos Aires, Argentina, C1120AAC
Novartis Investigative Site Recruiting
Buenos Aires, Argentina, C1125ABE
Novartis Investigative Site Recruiting
Cordoba, Argentina, 5000
Novartis Investigative Site Withdrawn
Cordoba, Argentina, X5000AAW
Novartis Investigative Site Recruiting
Cordoba, Argentina, X5003DCE
Novartis Investigative Site Recruiting
Cordoba, Argentina, X5016KEH
Novartis Investigative Site Recruiting
Mendoza, Argentina, 5500
Novartis Investigative Site Recruiting
Mendoza, Argentina, M5500CBA
Novartis Investigative Site Recruiting
Parana, Argentina, 3100
Novartis Investigative Site Recruiting
Santa Fe, Argentina, S3000FIL
Novartis Investigative Site Recruiting
Santa Fe, Argentina, S3000FWO
Australia, South Australia
Novartis Investigative Site Completed
Bedford Park, South Australia, Australia, 5041
Australia, Western Australia
Novartis Investigative Site Recruiting
Murdoch, Western Australia, Australia, 6150
Novartis Investigative Site Completed
Nedlands, Western Australia, Australia, 6009
Austria
Novartis Investigative Site Recruiting
Bludenz, Austria, 6700
Novartis Investigative Site Recruiting
Feldbach, Austria, 8330
Novartis Investigative Site Recruiting
Feldkirch, Austria, 6800
Novartis Investigative Site Recruiting
Grieskirchen, Austria, 4710
Novartis Investigative Site Withdrawn
Wien, Austria, A-1140
Belgium
Novartis Investigative Site Recruiting
Gosselies, BEL, Belgium, 6041
Novartis Investigative Site Completed
Hasselt, BEL, Belgium, 3500
Novartis Investigative Site Recruiting
Braine l'Alleud, Belgium, 1420
Novartis Investigative Site Recruiting
Brussel, Belgium, 1090
Novartis Investigative Site Recruiting
Bruxelles, Belgium, 1000
Novartis Investigative Site Recruiting
Bruxelles, Belgium, 1070
Novartis Investigative Site Recruiting
Eghezee, Belgium, 5310
Novartis Investigative Site Recruiting
Erpent, Belgium, 5100
Novartis Investigative Site Recruiting
Herentals, Belgium, 2200
Novartis Investigative Site Recruiting
Kortrijk, Belgium, 8500
Novartis Investigative Site Recruiting
Lebbeke, Belgium, 9280
Novartis Investigative Site Recruiting
Liege, Belgium, 4000
Novartis Investigative Site Recruiting
Malmedy, Belgium, 4960
Novartis Investigative Site Recruiting
Sint-Niklaas, Belgium, 9100
Bulgaria
Novartis Investigative Site Recruiting
Plovdiv, BGR, Bulgaria, 4000
Novartis Investigative Site Recruiting
Ruse, Bulgaria, 7002
Novartis Investigative Site Recruiting
Sofia, Bulgaria, 1202
Novartis Investigative Site Recruiting
Sofia, Bulgaria, 1463
Novartis Investigative Site Recruiting
Stara Zagora, Bulgaria, 6000
Canada, Alberta
Novartis Investigative Site Completed
Calgary, Alberta, Canada, T3C 1S5
Novartis Investigative Site Recruiting
Sherwood Park, Alberta, Canada, T8H 0N2
Canada, Ontario
Novartis Investigative Site Recruiting
Ajax, Ontario, Canada, L1S 2J5
Novartis Investigative Site Recruiting
Burlington, Ontario, Canada, L7N 3V2
Novartis Investigative Site Completed
Toronto, Ontario, Canada, M5T 3A9
Novartis Investigative Site Active, not recruiting
Toronto, Ontario, Canada, M6H 3M2
Novartis Investigative Site Recruiting
Toronto, Ontario, Canada, M9V 4B4
Novartis Investigative Site Recruiting
Windsor, Ontario, Canada, N8X 2G1
Novartis Investigative Site Recruiting
Windsor, Ontario, Canada, N8X 5A6
Canada, Quebec
Novartis Investigative Site Completed
Boisbriand, Quebec, Canada, J7H 1S6
Novartis Investigative Site Recruiting
Montreal, Quebec, Canada, H2X1P1
Novartis Investigative Site Recruiting
Montreal, Quebec, Canada, H3G 1L5
Novartis Investigative Site Recruiting
Pointe-Claire, Quebec, Canada, H9R 3J1
Novartis Investigative Site Active, not recruiting
Sherbrooke, Quebec, Canada, J1H 5N4
Novartis Investigative Site Recruiting
St-Jerome, Quebec, Canada, J7Z 5T3
Novartis Investigative Site Recruiting
Trois-Rivières, Quebec, Canada, G8T 7A1
Novartis Investigative Site Completed
Victoriaville, Quebec, Canada, G6P 6P6
Canada
Novartis Investigative Site Recruiting
Quebec, Canada, G1V 4W2
Novartis Investigative Site Recruiting
Quebec, Canada, G3K 2P8
Novartis Investigative Site Completed
Quebec, Canada, G8T 7A4
Chile
Novartis Investigative Site Recruiting
Santiago, Region Metropolitana, Chile, 7500692
Novartis Investigative Site Recruiting
Valparaiso, TX, Chile, 2341131
Novartis Investigative Site Recruiting
Curico, VII Region Del Maule, Chile, 3341643
Novartis Investigative Site Recruiting
Santiago, Chile, 9100
Novartis Investigative Site Recruiting
Santiago, Chile
China, Hainan
Novartis Investigative Site Recruiting
Haikou, Hainan, China, 570311
China, Hubei
Novartis Investigative Site Recruiting
Wuhan, Hubei, China, 430030
China, Jiangsu
Novartis Investigative Site Recruiting
Nanjing, Jiangsu, China, 210009
Novartis Investigative Site Recruiting
Suzhou, Jiangsu, China, 215006
China, Jilin
Novartis Investigative Site Recruiting
Changchun, Jilin, China, 130021
China, Liaoning
Novartis Investigative Site Recruiting
Shenyang, Liaoning, China, 110000
Novartis Investigative Site Recruiting
Shenyang, Liaoning, China, 110003
Novartis Investigative Site Recruiting
Shenyang, Liaoning, China, 110011
China, Shandong
Novartis Investigative Site Recruiting
Qingdao, Shandong, China, 266011
China, Shanghai
Novartis Investigative Site Recruiting
Shanghai, Shanghai, China, 200032
China, Shanxi
Novartis Investigative Site Recruiting
Xian, Shanxi, China, 710061
China, Sichuan
Novartis Investigative Site Recruiting
Chengdu, Sichuan, China, 610041
China
Novartis Investigative Site Recruiting
Beijing, China, 100730
Novartis Investigative Site Recruiting
Chengdu, China, 610083
Novartis Investigative Site Recruiting
Chongqing, China, 400037
Novartis Investigative Site Recruiting
Guangzhou, China, 510000
Novartis Investigative Site Recruiting
Shanghai, China, 200433
Novartis Investigative Site Recruiting
Tianjin, China, 300052
Colombia
Novartis Investigative Site Recruiting
Bogota, Colombia, 110111
Novartis Investigative Site Recruiting
Bogota, Colombia, 110221
Novartis Investigative Site Recruiting
Floridablanca, Colombia
Novartis Investigative Site Recruiting
Medellin, Colombia
Croatia
Novartis Investigative Site Recruiting
Zagreb, HRV, Croatia, 10 000
Novartis Investigative Site Recruiting
Petrinja, Croatia, 44250
Novartis Investigative Site Recruiting
Zadar, Croatia, 23000
Novartis Investigative Site Recruiting
Zagreb, Croatia, 10000
Denmark
Novartis Investigative Site Recruiting
Copenhagen NV, Denmark, DK-2400
Novartis Investigative Site Recruiting
Hvidovre, Denmark, 2650
Estonia
Novartis Investigative Site Recruiting
Tallinn, Estonia, 10117
Novartis Investigative Site Recruiting
Tallinn, Estonia, 10138
Novartis Investigative Site Recruiting
Tallinn, Estonia, 13419
Novartis Investigative Site Recruiting
Tartu, Estonia, 51014
Finland
Novartis Investigative Site Recruiting
Jyvaskyla, Finland, 40100
Novartis Investigative Site Recruiting
Turku, Finland, FIN-20100
France
Novartis Investigative Site Recruiting
Besancon Cedex, France, 25030
Novartis Investigative Site Recruiting
Montpellier, France, 34059
Germany
Novartis Investigative Site Recruiting
Koblenz, NRW, Germany, 56068
Novartis Investigative Site Recruiting
Cottbus, Sachsen, Germany, 03050
Novartis Investigative Site Recruiting
Geesthacht, Schleswig Holstein, Germany, 12502
Novartis Investigative Site Recruiting
Annaberg-Buchholz, Germany, 09456
Novartis Investigative Site Recruiting
Aschaffenburg, Germany, 63739
Novartis Investigative Site Recruiting
Berlin, Germany, 10119
Novartis Investigative Site Recruiting
Berlin, Germany, 10367
Novartis Investigative Site Recruiting
Berlin, Germany, 10717
Novartis Investigative Site Recruiting
Berlin, Germany, 12159
Novartis Investigative Site Recruiting
Berlin, Germany, 12203
Novartis Investigative Site Recruiting
Berlin, Germany, 12627
Novartis Investigative Site Recruiting
Berlin, Germany, 13057
Novartis Investigative Site Recruiting
Berlin, Germany, 13156
Novartis Investigative Site Recruiting
Bochum, Germany, D-44787
Novartis Investigative Site Recruiting
Bonn, Germany, 53119
Novartis Investigative Site Recruiting
Darmstadt, Germany, 64283
Novartis Investigative Site Recruiting
Frankfurt am Main, Germany, 60313
Novartis Investigative Site Recruiting
Frankfurt, Germany, 60389
Novartis Investigative Site Recruiting
Frankfurt, Germany, 60596
Novartis Investigative Site Withdrawn
Halberstadt, Germany, 38820
Novartis Investigative Site Recruiting
Halle, Germany, 06108
Novartis Investigative Site Terminated
Hamburg, Germany, 20357
Novartis Investigative Site Recruiting
Hamburg, Germany, 22143
Novartis Investigative Site Recruiting
Hamburg, Germany, 22299
Novartis Investigative Site Recruiting
Hamburg, Germany, 22335
Novartis Investigative Site Recruiting
Hannover, Germany, 30173
Novartis Investigative Site Recruiting
Hettstedt, Germany, 06333
Novartis Investigative Site Recruiting
Kamenz, Germany, 01917
Novartis Investigative Site Recruiting
Karlsruhe, Germany, 76199
Novartis Investigative Site Recruiting
Leipzig, Germany, 04103
Novartis Investigative Site Recruiting
Leipzig, Germany, 04275
Novartis Investigative Site Recruiting
Leipzig, Germany, 04357
Novartis Investigative Site Recruiting
Lübeck, Germany, 23558
Novartis Investigative Site Recruiting
Mainz, Germany, 55131
Novartis Investigative Site Recruiting
Mittweida, Germany, 09648
Novartis Investigative Site Recruiting
Neu Isenburg, Germany, 63263
Novartis Investigative Site Recruiting
Neuss, Germany, 41462
Novartis Investigative Site Recruiting
Potsdam, Germany, 14467
Novartis Investigative Site Recruiting
Rudersdorf, Germany, 15562
Novartis Investigative Site Terminated
Warendorf, Germany, 48231
Novartis Investigative Site Recruiting
Witten, Germany, 58452
Novartis Investigative Site Recruiting
Zerbst, Germany, 39261
Greece
Novartis Investigative Site Recruiting
Athens, GR, Greece, 115 27
Novartis Investigative Site Recruiting
Thessaloniki, GR, Greece, 564 03
Novartis Investigative Site Recruiting
Thessaloniki, GR, Greece, 564 29
Novartis Investigative Site Recruiting
Thessaloniki, GR, Greece, 570 10
Novartis Investigative Site Recruiting
Athens, Greece, 106 76
Novartis Investigative Site Completed
Athens, Greece, 12462
Novartis Investigative Site Recruiting
Athens, Greece, 175 62
Novartis Investigative Site Recruiting
Athens, Greece, GR 115 27
Novartis Investigative Site Recruiting
Thessaloniki, Greece, GR 570 10
Hungary
Novartis Investigative Site Recruiting
Budaors, HUN, Hungary, 2040
Novartis Investigative Site Recruiting
Budapest, HUN, Hungary, 1204
Novartis Investigative Site Recruiting
Eger, HUN, Hungary, 3300
Novartis Investigative Site Recruiting
Kapuvár, HUN, Hungary, 9330
Novartis Investigative Site Recruiting
Puspokladany, HUN, Hungary, 4150
Novartis Investigative Site Recruiting
Tata, HUN, Hungary, 2890
Novartis Investigative Site Recruiting
Balassagyarmat, Hungary, 2660
Novartis Investigative Site Recruiting
Budapest, Hungary, 1106
Novartis Investigative Site Recruiting
Budapest, Hungary, 1134
Novartis Investigative Site Recruiting
Godollo, Hungary, 2100
Novartis Investigative Site Completed
Kaposvar, Hungary, 7400
Novartis Investigative Site Recruiting
Komarom, Hungary, 2900
Novartis Investigative Site Recruiting
Mateszalka, Hungary, 4700
Novartis Investigative Site Recruiting
Nyiregyhaza, Hungary, H-4400
Novartis Investigative Site Recruiting
Szarvas, Hungary, 5540
Novartis Investigative Site Recruiting
Szeged, Hungary, 6722
Novartis Investigative Site Recruiting
Szeged, Hungary, 6772
Novartis Investigative Site Recruiting
Szigetszentmiklos, Hungary, H-2310
Novartis Investigative Site Recruiting
Szigetvar, Hungary, 7900
India
Novartis Investigative Site Recruiting
Guntur, Andhra Pradesh, India, 522 001
Novartis Investigative Site Recruiting
Hyderabad, Andhra Pradesh, India, 500 058
Novartis Investigative Site Recruiting
Vijayawada, Andhra Pradesh, India, 520008
Novartis Investigative Site Recruiting
Dehli, Delhi, India, 110063
Novartis Investigative Site Recruiting
New Delhi, Delhi, India, 110 060
Novartis Investigative Site Recruiting
Ahmedabad, Gujarat, India, 380 060
Novartis Investigative Site Recruiting
Ahmedabad, Gujarat, India, 380016
Novartis Investigative Site Recruiting
Ahmedabad, Gujarat, India, 380052
Novartis Investigative Site Recruiting
Gurgaon, Haryana, India, 122 002
Novartis Investigative Site Recruiting
Bangalore, Karnataka, India, 560060
Novartis Investigative Site Completed
Bangalore, Karnataka, India, 560074
Novartis Investigative Site Recruiting
Hubli, Karnataka, India, 580022
Novartis Investigative Site Recruiting
Mangalore, Karnataka, India, 575001
Novartis Investigative Site Recruiting
Mysore, Karnataka, India, 570001
Novartis Investigative Site Recruiting
Cherthala, Kerala, India, 688524
Novartis Investigative Site Recruiting
Kochi, Kerala, India, 683 594
Novartis Investigative Site Recruiting
Kozhikode, Kerala, India, 673008
Novartis Investigative Site Recruiting
Trivandrum, Kerala, India, 695029
Novartis Investigative Site Recruiting
Mumbai, Maharashtra, India, 401107
Novartis Investigative Site Recruiting
Nagpur, Maharashtra, India, 440010
Novartis Investigative Site Recruiting
Nagpur, Maharashtra, India, 440019
Novartis Investigative Site Recruiting
Pune, Maharashtra, India, 411 001
Novartis Investigative Site Recruiting
Pune, Maharashtra, India, 411007
Novartis Investigative Site Recruiting
Wardha, Maharashtra, India, 442004
Novartis Investigative Site Recruiting
Mohali, Punjab, India, 160 062
Novartis Investigative Site Recruiting
Bikaner, Rajasthan, India, 334003
Novartis Investigative Site Recruiting
Jaipur, Rajasthan, India, 302013
Novartis Investigative Site Recruiting
Jaipur, Rajasthan, India, 302020
Novartis Investigative Site Recruiting
Jaipur, Rajasthan, India, 302023
Novartis Investigative Site Withdrawn
Chennai, Tamil Nadu, India, 600100
Novartis Investigative Site Recruiting
Coimbatore, Tamil Nadu, India, 641 045
Novartis Investigative Site Recruiting
Madurai, Tamil NADU, India, 625107
Novartis Investigative Site Recruiting
Vellore, Tamil Nadu, India, 632 004
Novartis Investigative Site Recruiting
Chennai, Tamilnadu, India, 600037
Novartis Investigative Site Recruiting
Hyderabad, Telangana, India, 500 038
Novartis Investigative Site Recruiting
Hyderabad, Telangana, India, 500004
Novartis Investigative Site Recruiting
Kanpur, Uttar Pradesh, India, 208 002
Novartis Investigative Site Recruiting
DehraDun, Uttarakhand, India, 248001
Novartis Investigative Site Recruiting
Kolkata, West Bengal, India, 700 107
Novartis Investigative Site Recruiting
Ahmedabad, India, 380052
Ireland
Novartis Investigative Site Recruiting
Dublin, Ireland, 24
Israel
Novartis Investigative Site Recruiting
Ashkelon, Israel, 78278
Novartis Investigative Site Recruiting
Beer-Sheva, Israel, 8457108
Novartis Investigative Site Recruiting
Jerusalem, Israel, 9103102
Novartis Investigative Site Recruiting
Jerusalem, Israel, 91120
Novartis Investigative Site Recruiting
Kfar Saba, Israel, 4428164
Novartis Investigative Site Recruiting
Petach Tikva, Israel, 49100
Novartis Investigative Site Recruiting
Rehovot, Israel, 7610001
Italy
Novartis Investigative Site Recruiting
Bari, BA, Italy, 70124
Novartis Investigative Site Recruiting
Catania, CT, Italy, 95125
Novartis Investigative Site Recruiting
Catanzaro, CZ, Italy, 88100
Novartis Investigative Site Recruiting
Firenze, FI, Italy, 50134
Novartis Investigative Site Recruiting
Messina, ME, Italy, 98125
Novartis Investigative Site Recruiting
Negrar, VR, Italy, 37024
Novartis Investigative Site Recruiting
Ancona, Italy, 60127
Novartis Investigative Site Recruiting
Messina, Italy, 98125
Novartis Investigative Site Recruiting
Pordenone, Italy, 33170
Novartis Investigative Site Recruiting
Roma, Italy, 00168
Novartis Investigative Site Recruiting
Roma, Italy, 8-00168
Japan
Novartis Investigative Site Recruiting
Kasuga-city, Fukuoka, Japan, 816-0813
Novartis Investigative Site Recruiting
Ota-city, Gunma, Japan, 373-0807
Novartis Investigative Site Recruiting
Obihiro-city, Hokkaido, Japan, 080-0013
Novartis Investigative Site Recruiting
Tomakomai-city, Hokkaido, Japan, 053-8506
Novartis Investigative Site Withdrawn
Ako-city, Hyogo, Japan, 678-0239
Novartis Investigative Site Recruiting
Himeji-city, Hyogo, Japan, 671-0102
Novartis Investigative Site Recruiting
Himeji-city, Hyogo, Japan, 672-8064
Novartis Investigative Site Recruiting
Naka-gun, Ibaraki, Japan, 319-1113
Novartis Investigative Site Recruiting
Kawasaki-city, Kanagawa, Japan, 215-0021
Novartis Investigative Site Recruiting
Kawasaki-city, Kanagawa, Japan, 255
Novartis Investigative Site Recruiting
Yokohama-city, Kanagawa, Japan, 223-0059
Novartis Investigative Site Recruiting
Yokohama-city, Kanagawa, Japan, 231-8682
Novartis Investigative Site Completed
Yokohama-city, Kanagawa, Japan, 232-0064
Novartis Investigative Site Recruiting
Yokohama-city, Kanagawa, Japan, 236-0051
Novartis Investigative Site Recruiting
Matsusaka-city, Mie, Japan, 515-8544
Novartis Investigative Site Recruiting
Yokkaichi-city, Mie, Japan, 510-8561
Novartis Investigative Site Recruiting
Sendai-city, Miyagi, Japan, 980-0871
Novartis Investigative Site Recruiting
Kurashiki-city, Okayama, Japan, 712-8064
Novartis Investigative Site Recruiting
Okayama-city, Okayama, Japan, 702-8055
Novartis Investigative Site Recruiting
Kishiwada-city, Osaka, Japan, 596-8501
Novartis Investigative Site Recruiting
Takatsuki-city, Osaka, Japan, 569-1192
Novartis Investigative Site Completed
Yao-city, Osaka, Japan, 581-0011
Novartis Investigative Site Recruiting
Tokyo, Shibuya Ku, Japan, 150 0013
Novartis Investigative Site Recruiting
Hamamatsu-city, Shizuoka, Japan, 431-3192
Novartis Investigative Site Recruiting
Chuo-ku, Tokyo, Japan, 103-0027
Novartis Investigative Site Recruiting
Itabashi-ku, Tokyo, Japan, 173-8610
Novartis Investigative Site Active, not recruiting
Kokubunji-city, Tokyo, Japan, 185-0014
Novartis Investigative Site Recruiting
Nakano-ku, Tokyo, Japan, 164-0012
Novartis Investigative Site Recruiting
Ota-ku, Tokyo, Japan, 145-0063
Novartis Investigative Site Recruiting
Shinagawa-ku, Tokyo, Japan, 142-8666
Novartis Investigative Site Recruiting
Toshima ku, Tokyo, Japan, 170 0003
Latvia
Novartis Investigative Site Recruiting
Balvi, LVA, Latvia, 4501
Novartis Investigative Site Recruiting
Bauska, LVA, Latvia, LV-3901
Novartis Investigative Site Recruiting
Daugavpils, LVA, Latvia, LV-5417
Novartis Investigative Site Recruiting
Jurmala, LVA, Latvia, LV-2015
Novartis Investigative Site Recruiting
Rezekne, LVA, Latvia, LV-4600
Novartis Investigative Site Recruiting
Riga, LVA, Latvia, 1021
Novartis Investigative Site Recruiting
Riga, LV, Latvia, 1011
Novartis Investigative Site Recruiting
Riga, LV, Latvia, LV-1038
Novartis Investigative Site Recruiting
Daugavpils, Latvia, LV-5401
Novartis Investigative Site Recruiting
Riga, Latvia, LV 1002
Lebanon
Novartis Investigative Site Recruiting
Beirut, Lebanon, 1107 2020
Novartis Investigative Site Recruiting
Beirut, Lebanon, 166378
Lithuania
Novartis Investigative Site Recruiting
Vilnius, LTU, Lithuania, LT-04129
Novartis Investigative Site Withdrawn
Vilnius, LTU, Lithuania, LT-05263
Novartis Investigative Site Recruiting
Kaunas, LT, Lithuania, LT-50128
Novartis Investigative Site Recruiting
Vilnius, LT, Lithuania, 01117
Novartis Investigative Site Recruiting
Kaunas, Lithuania, LT-44320
Novartis Investigative Site Recruiting
Kaunas, Lithuania, LT-45130
Novartis Investigative Site Recruiting
Kaunas, Lithuania, LT-49449
Novartis Investigative Site Recruiting
Kaunas, Lithuania, LT-50154
Novartis Investigative Site Recruiting
Klaipeda, Lithuania, LT-92231
Novartis Investigative Site Recruiting
Klaipeda, Lithuania, LT-92288
Novartis Investigative Site Recruiting
Siauliai, Lithuania, LT-76231
Novartis Investigative Site Recruiting
Vilnius, Lithuania, 06122
Mexico
Novartis Investigative Site Recruiting
Guadalajara, Jalisco, Mexico, 44100
Novartis Investigative Site Recruiting
Guadalajara, Jalisco, Mexico, 44130
Novartis Investigative Site Recruiting
Guadalajara, Jalisco, Mexico, 44670
Novartis Investigative Site Recruiting
Zapopan, Jalisco, Mexico, 45200
Novartis Investigative Site Recruiting
Culiacan, MEX, Mexico, 80020
Novartis Investigative Site Recruiting
Monterrey, Nuevo Leon, Mexico, 64460
Novartis Investigative Site Recruiting
Distrito Federal, Mexico, 14000
Novartis Investigative Site Recruiting
Oaxaca, Mexico, 68000
Novartis Investigative Site Recruiting
Veracruz, Mexico, 91700
Netherlands
Novartis Investigative Site Recruiting
Breda, CK, Netherlands, 4818
Novartis Investigative Site Withdrawn
Amsterdam, Netherlands, 1090 HM
Novartis Investigative Site Recruiting
Eindhoven, Netherlands, 5623 EJ
Novartis Investigative Site Recruiting
Groningen, Netherlands, 9713 GZ
Novartis Investigative Site Recruiting
Harderwijk, Netherlands, 3840 AC
Novartis Investigative Site Recruiting
Heerlen, Netherlands, 6419 PC
Novartis Investigative Site Recruiting
Helmond, Netherlands, 5707 HA
Novartis Investigative Site Recruiting
Hengelo, Netherlands, 7555 DL
Novartis Investigative Site Recruiting
Hoofddorp, Netherlands, 1 2134
Novartis Investigative Site Recruiting
Rotterdam, Netherlands, 3045 PM
Novartis Investigative Site Recruiting
Zutphen, Netherlands, 7207 AE
Novartis Investigative Site Recruiting
Zwolle, Netherlands, 8025 AB
Peru
Novartis Investigative Site Recruiting
San Borja, Lima, Peru, 41
Novartis Investigative Site Recruiting
San Isidro, Lima, Peru, 27
Novartis Investigative Site Recruiting
San Miguel, Lima, Peru, 32
Novartis Investigative Site Recruiting
Lima, Peru, 14
Philippines
Novartis Investigative Site Recruiting
Lipa City, Batangas, Philippines, 4217
Novartis Investigative Site Recruiting
Manila, Metro Manila, Philippines, 1000
Novartis Investigative Site Recruiting
Bulacan, Philippines, 3020
Novartis Investigative Site Recruiting
Manila, Philippines, 1000
Novartis Investigative Site Recruiting
Quezon City, Philippines, 1100
Novartis Investigative Site Recruiting
Quezon City, Philippines, 1102
Poland
Novartis Investigative Site Recruiting
Ksawerow, POL, Poland, 95-054
Novartis Investigative Site Recruiting
Wejherowo, POL, Poland, 84-200
Novartis Investigative Site Recruiting
Bielsko-Biala, Poland, 43-300
Novartis Investigative Site Recruiting
Elblag, Poland, 82-300
Novartis Investigative Site Recruiting
Inowroclaw, Poland, 88-100
Novartis Investigative Site Recruiting
Krakow, Poland, 31-024
Novartis Investigative Site Recruiting
Krakow, Poland, 31-159
Novartis Investigative Site Recruiting
Lodz, Poland, 90-302
Novartis Investigative Site Recruiting
Ostrow Wielkopolski, Poland, 63-400
Novartis Investigative Site Recruiting
Sopot, Poland, 81-741
Novartis Investigative Site Recruiting
Warszawa, Poland, 01-868
Novartis Investigative Site Recruiting
Wroclaw, Poland, 50-445
Novartis Investigative Site Recruiting
Zawadzkie, Poland, 47-120
Portugal
Novartis Investigative Site Recruiting
Coimbra, Portugal, 3000-075
Novartis Investigative Site Active, not recruiting
Coimbra, Portugal, 3041-853
Novartis Investigative Site Active, not recruiting
Lisboa, Portugal, 1998 - 018
Novartis Investigative Site Recruiting
Porto, Portugal, 4100-180
Romania
Novartis Investigative Site Recruiting
Craiova, ROM, Romania, 200712
Novartis Investigative Site Recruiting
Deva, ROM, Romania, 330084
Novartis Investigative Site Recruiting
Timisoara, Timis, Romania, 300310
Novartis Investigative Site Completed
Arad, Romania, 310085
Novartis Investigative Site Recruiting
Arad, Romania, 310085
Novartis Investigative Site Recruiting
Bacau, Romania, 600252
Novartis Investigative Site Recruiting
Brasov, Romania, 500086
Novartis Investigative Site Recruiting
Brasov, Romania, 500283
Novartis Investigative Site Recruiting
Bucharest, Romania, 030317
Novartis Investigative Site Recruiting
Bucuresti, Romania, 050159
Novartis Investigative Site Recruiting
Cluj Napoca, Romania, 400139
Novartis Investigative Site Recruiting
Cluj Napoca, Romania, 400162
Novartis Investigative Site Recruiting
Cluj-Napoca, Romania, 400371
Novartis Investigative Site Recruiting
Constanta, Romania, 900591
Novartis Investigative Site Recruiting
Deva, Romania, 330162
Novartis Investigative Site Recruiting
Pitesti, Romania, 110084
Russian Federation
Novartis Investigative Site Recruiting
Barnaul, Russian Federation, 656024
Novartis Investigative Site Recruiting
Barnaul, Russian Federation, 656038
Novartis Investigative Site Recruiting
Barnaul, Russian Federation, 656045
Novartis Investigative Site Recruiting
Chelyabinsk, Russian Federation, 454021
Novartis Investigative Site Recruiting
Ivanovo, Russian Federation, 153005
Novartis Investigative Site Recruiting
Kazan, Russian Federation, 420012
Novartis Investigative Site Recruiting
Kemerovo, Russian Federation, 650002
Novartis Investigative Site Recruiting
Moscow, Russian Federation, 105077
Novartis Investigative Site Recruiting
Moscow, Russian Federation, 121309
Novartis Investigative Site Recruiting
Moscow, Russian Federation, 125993
Novartis Investigative Site Recruiting
Nizhny Novgorod, Russian Federation, 603011
Novartis Investigative Site Recruiting
Nizhny Novgorod, Russian Federation, 603018
Novartis Investigative Site Recruiting
Novosibirsk, Russian Federation, 630099
Novartis Investigative Site Recruiting
Novosibirsk, Russian Federation, 630102
Novartis Investigative Site Recruiting
Omsk, Russian Federation, 644112
Novartis Investigative Site Recruiting
Perm, Russian Federation, 614056
Novartis Investigative Site Recruiting
Perm, Russian Federation, 614068
Novartis Investigative Site Recruiting
Pskov, Russian Federation, 180007
Novartis Investigative Site Active, not recruiting
Pyatigorsk, Russian Federation, 357500
Novartis Investigative Site Recruiting
Saint Petersburg, Russian Federation, 191123
Novartis Investigative Site Recruiting
Saint Petersburg, Russian Federation, 194354
Novartis Investigative Site Recruiting
Saint Petersburg, Russian Federation, 197022
Novartis Investigative Site Recruiting
Saint Petersburg, Russian Federation, 199106
Novartis Investigative Site Recruiting
Saint-Petersburg, Russian Federation, 191186
Novartis Investigative Site Recruiting
Saint-Petersburg, Russian Federation, 192283
Novartis Investigative Site Recruiting
Saint-Petersburg, Russian Federation, 196143
Novartis Investigative Site Recruiting
Saratov, Russian Federation, 410012
Novartis Investigative Site Recruiting
Sestroretsk, Russian Federation, 197706
Novartis Investigative Site Recruiting
Smolensk, Russian Federation, 197022
Novartis Investigative Site Recruiting
Smolensk, Russian Federation, 214006
Novartis Investigative Site Recruiting
Smolensk, Russian Federation, 214019
Novartis Investigative Site Recruiting
St. Petersburg, Russian Federation, 191015
Novartis Investigative Site Recruiting
St.-Petersburg, Russian Federation, 193231
Novartis Investigative Site Recruiting
Tomsk, Russian Federation, 634063
Novartis Investigative Site Recruiting
Tver, Russian Federation, 170036
Novartis Investigative Site Recruiting
Ufa, Russian Federation, 450000
Novartis Investigative Site Recruiting
Ulyanovsk, Russian Federation, 432063
Novartis Investigative Site Recruiting
Vladikavkaz, Russian Federation, 362019
Novartis Investigative Site Recruiting
Volgograd, Russian Federation, 400120
Novartis Investigative Site Recruiting
Vsevolozhsk, Russian Federation, 188640
Novartis Investigative Site Completed
Yaroslavl, Russian Federation, 150000
Novartis Investigative Site Recruiting
Yaroslavl, Russian Federation, 150002
Novartis Investigative Site Recruiting
Yaroslavl, Russian Federation, 150003
Slovakia
Novartis Investigative Site Recruiting
Kosice, Slovak Republic, Slovakia, 040 01
Novartis Investigative Site Recruiting
Kosice, Slovak Republic, Slovakia, 04001
Novartis Investigative Site Recruiting
Kezmarok, Slovakia, 060 01
Novartis Investigative Site Recruiting
Kosice, Slovakia, 04001
Novartis Investigative Site Recruiting
Liptovsky Mikulas, Slovakia, 031 23
Novartis Investigative Site Recruiting
Poprad, Slovakia, 058 01
Novartis Investigative Site Recruiting
Presov, Slovakia, 080 01
Novartis Investigative Site Recruiting
Spisska Nova Ves, Slovakia, 052 01
Novartis Investigative Site Recruiting
Trencin, Slovakia, 91101
Novartis Investigative Site Recruiting
Zilina, Slovakia, 01207
Novartis Investigative Site Recruiting
Zvolen, Slovakia, 960 01
Slovenia
Novartis Investigative Site Recruiting
Golnik, Slovenia, 4204
Novartis Investigative Site Recruiting
Topolsica, Slovenia, 3326
South Africa
Novartis Investigative Site Recruiting
Berea, Durban, South Africa, 4001
Novartis Investigative Site Recruiting
Durban, Kwazulu Natal, South Africa, 4093
Novartis Investigative Site Recruiting
Middelburg, Mpumalanga, South Africa, 1050
Novartis Investigative Site Recruiting
Kempton Park, ZAF, South Africa, 1619
Novartis Investigative Site Recruiting
Cape Town, South Africa, 7531
Novartis Investigative Site Recruiting
Cape Town, South Africa, 7700
Novartis Investigative Site Recruiting
Cape Town, South Africa, 7764
Novartis Investigative Site Recruiting
Cape Town, South Africa, 7925
Novartis Investigative Site Completed
Midstream, South Africa, 1692
Spain
Novartis Investigative Site Recruiting
Malaga, Andalucia, Spain, 29010
Novartis Investigative Site Recruiting
Marbella, Andalucia, Spain, 29603
Novartis Investigative Site Recruiting
Sevilla, Andalucia, Spain, 41013
Novartis Investigative Site Recruiting
Esparraguera, Barcelona, Spain, 08292
Novartis Investigative Site Recruiting
Laredo, Cantabria, Spain, 39770
Novartis Investigative Site Recruiting
Vila-real, Castellon, Spain, 12540
Novartis Investigative Site Recruiting
Girona, Catalunya, Spain, 17007
Novartis Investigative Site Recruiting
Alzira, Comunidad Valenciana, Spain, 46600
Novartis Investigative Site Recruiting
Valencia, Comunidad Valenciana, Spain, 46015
Novartis Investigative Site Recruiting
Valencia, Comunidad Valenciana, Spain, 46017
Novartis Investigative Site Recruiting
Caceres, Extremadura, Spain, 10003
Novartis Investigative Site Withdrawn
Valdemoro, Madrid, Spain, 28342
Novartis Investigative Site Recruiting
Pamplona, Navarra, Spain, 31008
Novartis Investigative Site Recruiting
La Laguna, Santa Cruz De Tenerife, Spain, 38320
Novartis Investigative Site Withdrawn
A Coruna, Spain, 15006
Novartis Investigative Site Withdrawn
Cartagena, Spain, 30202
Novartis Investigative Site Recruiting
Leon, Spain, 24071
Novartis Investigative Site Withdrawn
Madrid, Spain, 28031
Novartis Investigative Site Recruiting
Zaragoza, Spain, 50015
Sweden
Novartis Investigative Site Recruiting
Goteborg, Sweden, 412 45
Novartis Investigative Site Recruiting
Lidingo, Sweden, 181 58
Novartis Investigative Site Recruiting
Linköping, Sweden, 581 85
Novartis Investigative Site Recruiting
Stockholm, Sweden, 111 57
Switzerland
Novartis Investigative Site Withdrawn
Basel, Switzerland, 4031
Novartis Investigative Site Recruiting
Gossau, Switzerland, 9200
Novartis Investigative Site Recruiting
Liestal, Switzerland, 4410
Novartis Investigative Site Recruiting
Lugano, Switzerland, 6900
Novartis Investigative Site Recruiting
St. Gallen, Switzerland, 9007
Thailand
Novartis Investigative Site Recruiting
Khon Kaen, THA, Thailand, 40002
Novartis Investigative Site Recruiting
Bangkok, Thailand, 10400
Novartis Investigative Site Recruiting
Bangkok, Thailand, 26120
Novartis Investigative Site Recruiting
Chiang Mai, Thailand, 50200
United Kingdom
Novartis Investigative Site Recruiting
Liskeard, Cornwall, United Kingdom, PL14 3XA
Novartis Investigative Site Recruiting
St Austell, Cornwall, United Kingdom, PL26 7RL
Novartis Investigative Site Recruiting
Torpoint, Cornwall, United Kingdom, PL11 2TB
Novartis Investigative Site Recruiting
Truro, GBR, United Kingdom, TR1 2JA
Novartis Investigative Site Recruiting
Waterlooville, GBR, United Kingdom, PO7 7AH
Novartis Investigative Site Recruiting
Bristol, South Gloucestershire, United Kingdom, BS37 4AX
Novartis Investigative Site Recruiting
Cardiff, Wales, United Kingdom, CF23 9PN
Novartis Investigative Site Completed
Birkenhead, United Kingdom, CH41 0DD
Novartis Investigative Site Recruiting
Cardiff, United Kingdom, CF14 4XW
Novartis Investigative Site Recruiting
London, United Kingdom, E9 6SR
Novartis Investigative Site Recruiting
Rotherham, United Kingdom, S65 1DA
Novartis Investigative Site Recruiting
Watford, United Kingdom, WD25 7NL
Vietnam
Novartis Investigative Site Recruiting
Ho Chi Minh, VNM, Vietnam, 700000
Novartis Investigative Site Recruiting
Hanoi, Vietnam, 100000
Novartis Investigative Site Recruiting
Ho Chi Minh, Vietnam, 700000
Sponsors and Collaborators
Novartis Pharmaceuticals

Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02571777    
Other Study ID Numbers: CQVM149B2302
First Posted: October 8, 2015    Key Record Dates
Last Update Posted: July 16, 2018
Last Verified: July 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Asthma
Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Fluticasone
Salmeterol Xinafoate
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action